Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Writing · gene therapy and CROs

The Role of a Contract Research Organisation in Gene Therapy Clinical Trials: Follow-Up, Vectors and Documentation

Gene therapy does not change the function of a contract research organisation (CRO). It changes four specific elements: the follow-up horizon, the unit of manufacture, the size of the recruitable population and the regulatory documentation set. All other activities — monitoring, data management, pharmacovigilance and reporting — are conventional work conducted under unconventional constraints. Programmes that fail usually do so on the first and the last of these four elements rather than on the science.

Pubrica AcademyWritten by the medical writing and biostatistics teams Reviewed byPubrica biostatistics team Published9 October 2026 Last checked9 October 2026 Reading time16 minutes Sources31, of which 29 peer-reviewed

There are 3,900 gene therapy clinical trials completed, ongoing or approved worldwide across 46 countries, a field large enough to have established conventions yet small enough that most sites conducting such a trial are doing so for the first time. For a research organisation, the practical question concerns not the nature of gene therapy but its effect on the operational plan: it extends the timeline beyond the period for which most trial infrastructure is designed, concentrates risk in a single administration that cannot be stopped, and complicates the statistics because populations are small. This article sets out the responsibilities of a CRO under these constraints and the points at which the work most often fails.

Gene therapy and the CRO at a glance

What gene therapy is
Delivery of genetic material into a patient’s own (somatic) cells to treat disease, either directly in the body (in vivo) or into cells modified outside it and returned (ex vivo)8
Approved products
22 in vivo and ex vivo products approved by 2023, according to one peer-reviewed review8
Trial activity
3,900 trials completed, ongoing or approved in 46 countries as of March 20234
Uses in cancer
Genes inserted into cancer cells, oncolytic viruses, engineered CAR T cells and RNA-based approaches8,29,30
What changes for a CRO
Follow-up horizon, unit of manufacture, population size and documentation set
Reading time
About 16 minutes, with 4 figures and 4 tables

Learning objectives

  • The global trial landscape — volume, geography and the growth of multicountry trials
  • The four elements of trial conduct that gene therapy changes, and the effect of each on the plan
  • The requirements that vector choice imposes on the protocol, the site and follow-up
  • Why long-term follow-up is the deliverable most often underspecified, and how it should be specified
  • The effects of small populations on endpoints and analysis
  • The documentation set that a gene therapy programme generates, and the allocation of responsibility for each document

Common misconceptions

  • “Gene therapy trials are simply small trials with complicated biology.” The structural difference is time rather than complexity. A single administration intended to have a durable effect produces a follow-up obligation that outlasts the usual contract period, the usual data system and often the usual study team.
  • “The field is still too immature to have operational conventions.” With 3,900 trials across 46 countries, and a meta-analysis of adeno-associated virus (AAV) applications spanning 136 clinical trials, there is a substantial accumulated evidence base. Treating each programme as unprecedented is a choice, and a costly one.
  • “Commercial questions are for later.” Glybera was priced at about one million US dollars per treatment and withdrawn from the European market in April 2017; Strimvelis launched at EUR 594,000 per treatment. Both were approved products. The evidence that a payer will require is a trial-design question, and it must be addressed while the protocol is being written.
  • “A multicountry trial is a scale-up of a single-country one.” Multicountry gene therapy trials rose from 130 in 2017 to 301, which is 7.7% of all trials. They remain a small minority because vector shipment, national advanced-therapy regulations and site qualification do not scale linearly.
  • “The CRO’s job ends at database lock.” For a durable single-administration therapy, regulatory interest in year five and year ten is as substantial as interest in week twelve, and a named party must be contractually responsible for collecting those data.

What gene therapy is: types, uses and examples

Gene therapy treats disease by delivering genetic material into a patient’s cells. Peer-reviewed reviews distinguish two practical routes. In in vivo therapy a vector carrying the gene is given directly to the patient; adeno-associated virus (AAV) vectors are widely used for this purpose, and the approved products LUXTURNA, which targets the RPE65 gene in inherited retinal dystrophy, and Zolgensma, which targets the SMN1 gene in spinal muscular atrophy, are both AAV-based 8. In ex vivo therapy cells are removed from the patient, genetically modified outside the body and returned; retroviral and lentiviral vectors are used to modify cells such as CD34+ haematopoietic cells or T cells in this way 8.

Both routes are forms of somatic gene therapy: they alter non-reproductive cells, so the change is confined to the treated person. Germline modification, which would alter eggs, sperm or embryos and be inherited, is treated in the literature as a separate category with its own ethical and regulatory implications 31. Every approved product discussed on this page is somatic.

Types of gene therapy by target cell and route of delivery

TypeWhat is modifiedHow the gene is deliveredApproved examples described in the literature
Somatic, in vivoNon-reproductive cells inside the patient’s body; the change is not inheritedA vector, most often adeno-associated virus (AAV), administered directlyLUXTURNA (RPE65 gene, inherited retinal dystrophy) and Zolgensma (SMN1 gene, spinal muscular atrophy), both AAV-based
Somatic, ex vivoPatient cells removed, genetically modified outside the body and returnedRetroviral or lentiviral vectors, for example into CD34+ haematopoietic cells or T cellsLentiviral products including Kymriah (tisagenlecleucel), which delivers a chimeric antigen receptor
GermlineEggs, sperm or embryos, so that the change would be inheritedNot a route used by the approved products described hereNone; germline modification raises ethical and regulatory questions distinct from somatic therapy

Compiled from two peer-reviewed reviews: Shchaslyvyi et al. (2023) for vectors and approved products, and Bonowicz et al. (2025) for the somatic–germline distinction. Product names are given as examples, not as a complete list.

Cancer has been one of the principal fields of use. One strategy is literally to insert a gene into cancer cells: in gene-directed enzyme prodrug therapy, tumour cells are given a gene encoding an enzyme, such as an engineered cytochrome P450, that converts a chemotherapy prodrug into its active form within the tumour 29. Other strategies use viruses that act on tumour cells, T cells engineered ex vivo to carry a chimeric antigen receptor, and nanoparticle delivery of RNA interference or gene-editing components 8,30.

Gene therapy in cancer treatment: main strategies and examples

StrategyWhat is doneExample reported in the cited reviews
Inserting genes into cancer cellsA gene is introduced into tumour cells so that they convert an inactive prodrug into a cytotoxic drug (gene-directed enzyme prodrug therapy, GDEPT)Engineered cytochrome P450 enzymes studied in preclinical and clinical work
Oncolytic and gene-carrying virusesA virus that replicates in, or delivers a gene to, tumour cellsIMLYGIC, approved by the US FDA in 2015 for melanoma; Oncorine, approved in China in 2005 for nasopharyngeal cancer
Engineered immune cellsThe patient’s T cells are modified ex vivo to express a chimeric antigen receptor and reinfusedCAR T-cell products such as Kymriah, delivered with lentiviral vectors
RNA interference and gene editingsiRNA, mRNA or gene-editing components are carried into cancer cells, often in nanoparticlesPolymer, lipid and inorganic nanoparticle systems under development

Sources: Shchaslyvyi et al. (2023); Carrera-Pacheco et al. (2024); Wang et al. (2025). Approval years are those stated in the cited review.

Gene therapy clinical trials recorded worldwide (completed, ongoing or approved)

2012 update1,843 trials, 31 countries1,843
2017 update2,597 trials, 38 countries2,597
2023 update3,900 trials, 46 countries3,900
Figure 1. Cumulative counts from three successive updates of the Journal of Gene Medicine worldwide trials database (June 2012, November 2017 and March 2023). Bar lengths are proportional to the 2023 count. The counts describe activity, not success.27,28,4

The field has grown steadily. Successive updates of the same worldwide database recorded 1,843 trials in 31 countries in June 2012, 2,597 trials in 38 countries in November 2017, and 3,900 trials in 46 countries in March 2023 27,28,4. Approvals have followed, from Gendicine in China in 2003 to 22 approved in vivo and ex vivo products by 2023 8.

2003Gendicine (China)Approved by China’s State FDA for carcinoma8
2005Oncorine (China)Approved for nasopharyngeal cancer8
2011Neovasculgen (Russia)Approved for atherosclerotic peripheral arterial disease8
2015IMLYGIC (United States)Approved by the FDA for melanoma8
202322 approved productsIn vivo and ex vivo products approved across regulators, as counted by Shchaslyvyi et al.8
Figure 2. Selected gene therapy approvals, as reported in a 2023 peer-reviewed review of approved products and vectors. A selection, not a complete regulatory history.8

From product type to trial operations

Each of the product types above reaches patients only through clinical trials, and most sponsors run those trials with a contract research organisation (CRO). The type of gene therapy determines much of the operational work: an in vivo AAV product brings vector handling and shedding questions, an ex vivo cell product brings a manufacturing chain that runs through the trial itself, and both bring a single administration whose effect is intended to last for years. The rest of this article sets out what that means for the CRO.

Size and geographical distribution of the field

Several figures merit attention, because they indicate where experience is concentrated and therefore where the operational risk lies.

There are 3,900 gene therapy clinical trials completed, ongoing or approved worldwide, across 46 countries 4. The United States accounts for 2,054 of them, or 52.7%; China for 651, or 16.7%; and the United Kingdom for 245, or 6.3% 4. Multicountry trials have grown from 130 in 2017 to 301, which is 7.7% of all trials 4,21.

Three operational implications follow. First, more than half the world’s accumulated trial experience is concentrated in one country, so a programme conducted elsewhere frequently works with sites, ethics committees and regulators that have less institutional experience of this product class. This is a site-qualification and training problem rather than a scientific one, and it can be budgeted for if it is recognised early.

Second, at 7.7%, multicountry trials remain a small minority of the field even after more than doubling from 130. This is informative: if cross-border conduct were straightforward, the share would be expected to be higher, given how small the eligible populations are. The obstacles are practical — shipping a live vector, satisfying different national advanced-therapy requirements, and qualifying sites that may each be treating one or two patients.

Third, the distribution of trials indicates where the comparator evidence and the natural-history data will have been generated, which is relevant when a single-arm design must be justified to a regulator or a payer. Our pages on CRO-side research support and clinical trial support cover the operational side of that.

Where the world’s gene therapy trials are

TrialsShare of all trialsWhat it implies operationally
Worldwide total (completed, ongoing or approved)3,900across 46 countriesA substantial accumulated base; treating a programme as unprecedented is a choice
United States2,05452.7%More than half the institutional experience is concentrated in one country
China65116.7%The second concentration of site and regulator experience
United Kingdom2456.3%The largest European contributor in this count
Multicountry trials301 (up from 130 in 2017)7.7%More than doubled yet still a small minority; cross-border conduct is particularly difficult in this field

Counts of gene therapy clinical trials completed, ongoing or approved worldwide, as reported in the trial landscape analysis cited for this article. Shares are of all trials in that count. The figures describe activity, not outcomes.

Four operational differences introduced by gene therapy

Setting aside the biology, four structural features distinguish a gene therapy programme from a conventional small-molecule one. Each has a specific operational consequence, and they merit separate consideration because they are usually discussed as a single undifferentiated difficulty.

The administration is a single event and it cannot be withdrawn. There is no dose reduction, no washout and no discontinuation 9,26. Everything that would normally be managed by stopping the drug must instead be managed by selection, by pre-treatment assessment, and by a plan for an adverse event that cannot be reversed. This places greater weight on eligibility criteria and on the informed consent discussion, which must address irreversibility explicitly.

The intended effect is durable, so the follow-up horizon is long. A therapy intended to work for years must be observed for years, which is a different operational problem from a twelve-week endpoint. The follow-up outlasts staff, data systems and often contracts.

The product is biological and the manufacturing is part of the trial. Batch, titre, vector lot and release testing are study variables rather than background facts, and the chain between manufacture and administration is short, temperature-dependent and intolerant of error 26. Site readiness includes handling capability, not just clinical capability.

The population is small. Many indications are rare, and the eligible population at any one site may be in single figures. This constrains the design before any statistical consideration arises, and it explains why single-arm studies with external or natural-history comparison are common in this field rather than exceptional 9.

The four structural differences, and what each one changes in the plan

What is differentWhat it changes operationallyWhere it is usually missed
Single irreversible administration — no dose reduction, washout or discontinuationGreater weight on eligibility criteria, pre-treatment assessment and a plan for the adverse event that cannot be reversedInformed consent that does not state irreversibility in the patient’s own terms
Durable intended effect — the claim concerns yearsFollow-up horizon exceeds the study team, the database and often the contract; durability requires a pre-specified endpointA long-term follow-up clause with no dataset, no owner and no budget
Biological product, manufacturing inside the trialBatch, titre and lot become study variables; cold chain and handling capability become site selection criteriaSite qualification run against a generic capability questionnaire
Small eligible populationSingle-arm design with a pre-specified external or natural-history comparison; endpoint must be sensitive at the available nA comparison assembled after results exist rather than specified in the protocol

A working operational summary for programme planning, derived from the trial conduct requirements described in the gene therapy literature cited for this article. Not a regulatory classification.

1Eligibility, pre-treatment assessment and consent that states irreversibility in plain languageBefore dosing
2Single administration of a product whose batch, titre and lot are recorded as study variablesDay 0
3Parent-study follow-up to the primary endpoint and database lockMonths
4Separate long-term follow-up protocol with its own owner, dataset and budgetYears
Figure 3. The lifecycle of a single-administration gene therapy trial as seen by a CRO (illustrative). Step 4 is the one most often left without a named owner; its duration is set by the regulator and the product, not by this figure.

Protocol requirements imposed by vector choice

The choice of vector is not solely a scientific decision. It determines a set of operational requirements that must be written into the protocol, the site qualification checklist and the monitoring plan.

Adeno-associated virus vectors are the most studied delivery system in the clinical setting: a meta-analysis of AAV usage in clinical settings analysed AAV applications across 136 clinical trials 8,15. That accumulated base is useful because the operational questions are well characterised: pre-existing immunity to the capsid as an eligibility criterion, and therefore a screening assay that must be available and validated at every site; immune responses to the vector as an anticipated adverse event class with an associated monitoring schedule; and shedding, which raises containment and sample-handling requirements that affect laboratory contracts rather than the clinical protocol 9,15.

Whatever the vector, three matters must be decided and documented early. First, which assays define eligibility, and whether every site can perform them or samples must be shipped to a central laboratory. Second, what biological monitoring the follow-up schedule requires, for how long, and who funds it after the primary endpoint. Third, what the containment and handling requirements imply for site selection, because a site that cannot handle the product cannot participate in the study, however suitable its patient population.

This is the area in which a CRO contributes most substantially, although its contribution is seldom visible. Qualifying sites against a product-specific handling and assay requirement, rather than against a generic capability questionnaire, prevents the most costly category of mid-study problem: a site that enrolled a patient it could not properly assess.

Site qualification checklist for a gene therapy trial

  • Confirm handling capability for the specific vector class, including storage temperature and cold-chain receipt.
  • Confirm that eligibility assays can be run locally or that a validated shipping route to a central laboratory exists.
  • Confirm shedding and biosafety procedures appropriate to the vector, and that site staff are trained in them.
  • Record how batch, titre and lot will be captured for each administration.
  • Confirm that the site can support long-term follow-up contacts after the parent study closes.
  • Qualify the site against the product rather than a generic capability questionnaire.

Long-term follow-up as the most frequently underspecified deliverable

If one part of a gene therapy programme is systematically weaker than the rest, it is long-term follow-up. The protocol states that patients will be followed for long-term safety, the regulator expects something specific, and the operational plan for the later years is not developed in anything approaching the detail of the plan for the first few months 26.

The difficulty is not scientific. Long-term follow-up crosses boundaries that trial infrastructure is not designed to cross. The study team disperses. The database is designed for a study with a defined end. The site’s research staff change. The patient relocates, changes clinician, or simply stops attending once well — which in a successful gene therapy is the expected outcome and therefore the expected mechanism of attrition.

A specified long-term follow-up plan answers five questions in writing. What is collected, as a short defined dataset rather than a full visit schedule. At what intervals, with the intervals lengthening over time. By whom, with a named responsible party for each period, including after the primary study closes. Through what system, which is usually a registry or a separate long-term protocol rather than the parent trial database. And how patients will be retained, which requires a consent that anticipates the duration, a contact strategy that survives changes of address, and an acknowledgement that a patient who is well has no clinical reason to attend.

The comparison below concerns the single clause in which this most often fails. Our pages on post-market surveillance, clinical study protocols and study database build cover the infrastructure this implies.

The long-term follow-up clause in a protocol

Obligation stated, plan absent

Patients will be followed up for 12 months following administration to assess safety and efficacy. Long-term follow-up for delayed adverse events will be conducted in accordance with applicable regulatory requirements.

“In accordance with applicable regulatory requirements” is not a plan. It names no dataset, no interval, no duration and no system, so there is nothing for a monitor to monitor or for a budget to fund.

No owner. The parent study team disperses after database lock, and an obligation with no named owner is, in practice, held by no one.

No funding beyond the primary endpoint. Long-term follow-up costed within the parent study budget ends when that budget does, which is years before the obligation ends.

Durability is not specified as an endpoint. For a therapy whose central claim is a durable effect, leaving durability to descriptive follow-up means the claim is never formally tested, and an unspecified claim is likely to be discounted by a regulator or payer.

No retention strategy, despite a predictable mechanism of attrition. A patient in whom a single-administration therapy is effective has no clinical reason to return, so the patients most likely to be lost are those in whom the therapy succeeded.

Dataset, intervals, owner and retention all specified

Patients will be followed in the parent study for 12 months, after which they will be enrolled into a dedicated long-term follow-up protocol running to 15 years post-administration, for which consent is obtained at the same time as consent to the parent study. The long-term dataset is deliberately short — vital status, the pre-specified durability endpoint, hospitalisations, new malignancy, immunosuppressive or replacement therapy use, and pregnancy outcomes — and is collected at 18 and 24 months and annually thereafter, with the final five years collected by annual contact rather than clinic visit. The sponsor’s pharmacovigilance function owns the dataset for the full duration, with a named medical monitor, a funding line that runs to year 15 independently of the parent study budget, and a standing registry rather than the parent trial database as the system of record. Because patients in whom the therapy succeeds have no clinical reason to attend, retention is managed by annual contact through two nominated routes recorded at consent, by an agreement with the treating centre to flag transfers of care, and by a patient-facing annual summary of what the follow-up has shown.

A short, named dataset makes the obligation achievable: a five-field annual collection can realistically be sustained for fifteen years, whereas a full visit schedule cannot.

Intervals widen over time, aligning data collection with the residual uncertainty rather than repeating the early schedule indefinitely.

A named owner, a named medical monitor and a funding line independent of the parent study ensure that the plan continues beyond the end of the study in which it was written.

Durability is a pre-specified endpoint with a measurement horizon, which allows it to be cited to a regulator and used in a payer submission.

Consent is taken once for the whole duration and retention is designed around the known attrition mechanism, including contact routes recorded at consent and a reason for the patient to stay engaged.

For a single-administration therapy with a durable intended effect, the long-term follow-up plan is not an appendix to the evidence; it is where the product’s central claim is either substantiated or left unproven.

Takeaway: follow-up is a protocol, not a clause

For a therapy given once with an effect intended to last, the long-term follow-up plan carries the product’s central claim. It needs a short named dataset, widening intervals, an owner and a budget that outlive the parent study.

Small populations, endpoints and statistical analysis

The small-population constraint is the one that most alters the statistical and reporting work, and it does so before any analysis is run, at the point at which the endpoint is chosen.

With an eligible population in single or low double figures per site, a conventionally powered superiority trial against an active comparator is often not feasible. The feasible alternative is a single-arm study against a pre-specified external comparison — natural-history data, a historical cohort, or the patient’s own pre-treatment course — and the credibility of the entire programme then depends on how and when that comparison was specified. Specified in the protocol with a stated source and stated handling of differences, it constitutes a design. Assembled after the results are available, it constitutes a methodological problem.

Three consequences follow for the analysis plan. The endpoint must be sensitive enough to detect an effect with the numbers actually available, which usually requires a continuous or time-to-event measure rather than a dichotomous one. The durability question requires its own pre-specified endpoint rather than being left to descriptive follow-up, because durability is the central claim of the product class and a claim that was not pre-specified is likely to be discounted by a regulator 9,26. The handling of missing data must also be planned for the attrition mechanism described above, in which the patients most likely to be lost are those doing well.

Our statistical analysis plan support and biostatistics services cover this work, and epidemiological designs for clinical trials sets out what an external comparison can and cannot support.

Conduct of multicountry trials

Multicountry gene therapy trials rose from 130 in 2017 to 301, now 7.7% of all trials 4,21. Given that small eligible populations create strong pressure to recruit internationally, the modest share is itself the finding: cross-border conduct is more difficult in this field than in most.

There are three reasons, each with an operational response. The product must physically arrive in a viable state, which makes cold-chain and import documentation a critical path item rather than a logistical detail; in a study with a single patient per site, an import delay results in a lost patient rather than a delay. National requirements for advanced therapies differ in ways that the general clinical trial framework does not harmonise, so the regulatory plan is country-specific and sequential rather than a single submission replicated 21,26. Finally, site qualification cannot be delegated to a generic capability assessment when each site may treat one or two patients yet must still be able to handle the product, perform or ship the eligibility assays, and sustain the long-term follow-up.

The practical implication for planning is that the country list should be driven by product logistics and regulatory feasibility as much as by patient availability. A country with eligible patients and no viable route for the vector is not a recruiting country. Our regulatory writing and compliance support cover the submission side.

Pricing considerations in protocol development

Two approved gene therapies illustrate the point. Glybera was priced at about one million US dollars per treatment and withdrawn from the European market in April 2017. Strimvelis launched at EUR 594,000 per treatment 21.

These cases are not evidence of excessive pricing or regulatory failure. They indicate that technical and regulatory success is not sufficient, and that the gap is usually evidentiary: a payer deciding whether to fund a single very expensive administration needs to know how long the effect lasts, what happens to patients in whom it does not, and what the comparator pathway costs over the same horizon. These are all questions about data, and the data exist only if the trial was designed to generate them.

Several practical implications follow for study design. Durability should be a pre-specified endpoint with a stated measurement horizon, not a descriptive observation. The comparator should be the real-world care pathway that the therapy would displace, described in sufficient detail to be costed. Health-economic data — resource use, hospitalisations, time off treatment — are inexpensive to collect prospectively and effectively impossible to reconstruct afterwards, so the decision to collect them is made once, at the protocol stage 13,14. The long-term follow-up plan is the mechanism that generates the durability evidence, which is a further reason not to leave it vague.

Our pages on health economics, cost-effectiveness modelling and market access evidence cover the requirements of a payer submission, and should be consulted before the protocol is finalised.

~$1 millionper treatment: Glybera’s price
April 2017Glybera withdrawn from the European market
EUR 594,000per treatment: Strimvelis at launch

Two approved gene therapies and their commercial outcomes, as reported in the gene therapy pricing and market access literature cited for this article. Approval and reimbursement are separate problems.

The documentation set and allocation of responsibility

A gene therapy programme generates the standard regulatory document set with two additions and several modifications. Listing them is useful principally because the ownership of each is often unclear at the point at which it matters.

The protocol and its statistical analysis plan carry more weight than in a conventional study, because the external comparison and the durability endpoint must be pre-specified in them or they are not pre-specified at all. The investigator’s brochure must cover the vector class and its known adverse event profile, which is where the accumulated AAV experience across 136 trials becomes directly useful 15. The informed consent document must address irreversibility, the long follow-up duration, shedding and containment requirements, and any requirement for long-term sample storage — see our informed consent form support.

The additions are a long-term follow-up plan or protocol, as a document in its own right with its own owner and its own funding line, and a risk management plan that treats the irreversible administration as the central risk rather than as one entry among many. Our pages on risk management plans and periodic safety reporting cover the safety documentation, and CTD module summaries and the clinical study report cover the submission end.

Ownership warrants particular attention. A named owner should be assigned to the long-term follow-up plan at the same time as the protocol author, and that owner should be given a budget that extends beyond the primary endpoint. A follow-up obligation with no owner and no budget is likely to become an inspection finding.

Interpretation and limitations of the available figures

Three limitations apply to the foregoing.

The trial counts describe activity, not success. The figures of 3,900 trials completed, ongoing or approved across 46 countries, and 2,054 of them in the United States, indicate where the work is taking place 4. They do not indicate how many produced a licensed product, and this page does not claim a success rate because no such figure appears in its sources.

The AAV meta-analysis across 136 clinical trials is a substantial base for that vector class and does not generalise to others 15. Where a programme uses a different delivery system, the operational requirements must be derived from that system’s own evidence rather than borrowed.

The two pricing examples concern only two products. Glybera at about one million dollars per treatment with withdrawal from the European market in April 2017, and Strimvelis at EUR 594,000 at launch, demonstrate that approval does not guarantee commercial viability 21. They do not establish a general relationship between price and market outcome, and nothing here should be read as a benchmark for pricing.

The operational argument remains valid despite all three caveats, because it does not depend on the figures: a single irreversible administration with a durable intended effect in a small population creates a long follow-up obligation and a design problem, and programmes that address both explicitly at the protocol stage avoid discovering them later.

Key points

Key points

Gene therapy is a sufficiently mature field to have established conventions — 3,900 trials completed, ongoing or approved across 46 countries, with 2,054 in the United States, 651 in China and 245 in the United Kingdom, and an AAV meta-analysis spanning 136 clinical trials — and a CRO’s work on such a trial is conventional work under four unconventional constraints. The administration is single and irreversible, which places greater weight on eligibility and consent. The intended effect is durable, which creates a follow-up obligation that outlasts the study team, the database and usually the budget. The product is biological, which makes handling capability a criterion for site selection. The population is small, which necessitates single-arm designs whose credibility depends entirely on an externally sourced comparison specified in the protocol rather than assembled afterwards. Multicountry trials rose from 130 in 2017 to 301, still only 7.7% of the field, which indicates the difficulty of cross-border conduct in this area. The commercial record — Glybera at about one million dollars per treatment, withdrawn from the European market in April 2017, and Strimvelis at EUR 594,000 at launch — is the reason that durability and resource-use data belong in the protocol rather than in a later study.

Application to your study

Application to your study

  1. The long-term follow-up plan should be written as a separate document with its own owner and budget. It should specify a short defined dataset, widening intervals, a named responsible party for each period, and a registry rather than the parent trial database.
  2. Durability should be pre-specified as an endpoint. For a product class whose central claim is a durable effect, descriptive follow-up is not a substitute, and an unspecified claim is likely to be discounted.
  3. The external comparison should be specified in the protocol, together with its source. A natural-history or historical comparison named before results are available constitutes a design element; the same comparison identified afterwards constitutes a methodological problem.
  4. Sites should be qualified against the product rather than through a generic questionnaire. Qualification should address handling and cold-chain capability, the availability of eligibility assays or a shipping route to a central laboratory, and the capacity to sustain long-term follow-up.
  5. Cold-chain and import documentation should be treated as a critical path item in any multicountry plan. In a study enrolling one or two patients per site, an import delay results in a lost patient rather than a delayed visit.
  6. Irreversibility and follow-up duration should be explained in the consent document in plain language. The explanation should include sample storage, shedding precautions and the consequences if the therapy is ineffective.
  7. Resource use should be collected prospectively. Hospitalisations, time off alternative treatment and care pathway contacts are inexpensive to collect contemporaneously and cannot be reconstructed later.

Frequently asked questions

There are 3,900 gene therapy clinical trials completed, ongoing or approved worldwide, spread across 46 countries. The distribution is highly concentrated: the United States accounts for 2,054 trials, or 52.7% of the total; China for 651, or 16.7%; and the United Kingdom for 245, or 6.3%. Multicountry trials have grown from 130 in 2017 to 301, which is 7.7% of all trials. The practical significance of the concentration is that more than half the institutional experience — among sites, ethics committees and regulators — sits in one country, so a programme run elsewhere should budget for site training and longer regulatory lead times rather than assuming the familiarity that the trial counts might suggest.

The functions are conventional; the constraints are not. Four factors change. The administration is single and irreversible, so there is no dose reduction or discontinuation available, and greater weight falls on eligibility criteria, pre-treatment assessment and the consent discussion. The intended effect is durable, so follow-up continues for years and outlasts the study team, the database and often the contract. The product is biological, so batch, titre and lot are study variables and handling capability becomes a site selection criterion rather than a logistical detail. The population is small, which necessitates single-arm designs with external comparison. Monitoring, data management, pharmacovigilance and reporting are then conventional work performed under those four constraints.

Because it crosses boundaries that trial infrastructure is not designed to cross. The study team disperses after database lock, the database was designed for a study with a defined end, site research staff change, and the patient in whom the therapy was effective has no clinical reason to continue attending, so the patients most likely to be lost are those in whom it succeeded. A clause stating that follow-up will be conducted in accordance with applicable requirements names no dataset, no interval, no owner and no funding, so nothing can be monitored or budgeted. A workable plan specifies a short dataset, intervals that widen over time, a named owner with a funding line independent of the parent study, a registry as the system of record, and a retention strategy with contact routes recorded at consent.

Adeno-associated virus vectors are the most studied in the clinical setting — a meta-analysis of AAV usage analysed AAV applications across 136 clinical trials. The practical value of that base is that the operational questions are well characterised. Pre-existing immunity to the capsid is commonly an eligibility criterion, which means that a screening assay must be validated and either available at every site or supported by a shipping route to a central laboratory. Immune responses to the vector form an anticipated adverse event class with an associated monitoring schedule. Shedding raises containment and sample-handling requirements that affect laboratory contracts and site selection. For other delivery systems, these requirements must be derived from that system’s own evidence rather than borrowed from AAV.

That tension is precisely the finding. Multicountry trials more than doubled from 130 in 2017 to 301, yet still represent only 7.7% of all trials, despite strong pressure to recruit internationally from rare-disease populations. Three obstacles account for this. The product must physically arrive in a viable state, which makes cold chain and import documentation a critical path item; in a study treating one or two patients per site, an import delay results in a lost patient rather than a delayed visit. National requirements for advanced therapies differ in ways that the general clinical trial framework does not harmonise, so regulatory work is country-specific and sequential. Finally, site qualification cannot be delegated to a generic assessment when each site must handle the product and sustain years of follow-up.

No, as two approved products illustrate. Glybera was priced at about one million US dollars per treatment and withdrawn from the European market in April 2017. Strimvelis launched at EUR 594,000 per treatment. Approval and reimbursement are separate decisions based on different evidence: a payer asked to fund a single very expensive administration needs to know how long the effect lasts, what happens to patients in whom it does not work, and what the displaced care pathway costs over the same horizon. These are data questions, and the data exist only if the trial was designed to generate them; they cannot be reconstructed. For this reason, durability endpoints and prospective resource-use collection belong in the protocol discussion.

Usually as a single-arm study with a pre-specified external comparison — natural-history data, a historical cohort, or the patient’s own pre-treatment course. The credibility of the programme then depends almost entirely on when and how that comparison was specified: named in the protocol with a stated source and a stated approach to differences between the groups, it constitutes a design; assembled once results are available, it constitutes a problem that a regulator will identify. Three further consequences follow. The endpoint must be sensitive at the sample size actually available, which favours continuous or time-to-event measures over dichotomous ones. Durability requires its own pre-specified endpoint. The missing-data plan must anticipate that the patients most likely to withdraw are those doing well.

Two additions and several modifications. The additions are a long-term follow-up plan or protocol as a document in its own right — with its own owner, dataset and funding line extending past the primary endpoint — and a risk management plan that treats the irreversible single administration as the central risk rather than one entry among many. The modifications are as follows: the protocol and statistical analysis plan carry the pre-specified external comparison and the durability endpoint, and so bear more weight than in a conventional study; the investigator’s brochure must cover the vector class and its known adverse event profile; and the informed consent document must address irreversibility, the follow-up duration, shedding and containment, and any long-term sample storage. An owner should be assigned to the follow-up plan when the protocol author is assigned.

References

  1. U.S. Food and Drug Administration. Questions and Answers Regarding Enhancements to the Inactive Ingredient Database (IID). U.S. Food and Drug Administration (CDER). 2019. read 9 October 2026. fda.gov
  2. International Council for Harmonisation; U.S. Food and Drug Administration (CDER/CBER). Guidance for Industry Q8(R2) Pharmaceutical Development. U.S. Department of Health and Human Services, Food and Drug Administration. 2009;Revision 2. read 9 October 2026. fda.gov
  3. Hu B, Korsos V, Palomba ML. Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas. Frontiers in Oncology. 2024;14:1394057. doi:10.3389/fonc.2024.1394057 read 9 October 2026. doi.org/10.3389/fonc.2024.1394057
  4. Ginn SL, Mandwie M, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2023-an update. The Journal of Gene Medicine. 2024;26(8):e3721. doi:10.1002/jgm.3721 read 9 October 2026. doi.org/10.1002/jgm.3721
  5. Estape Senti M, Garcia Del Valle L, Schiffelers RM. mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond. Advanced Drug Delivery Reviews. 2024;206:1-17. doi:10.1016/j.addr.2024.115190 read 9 October 2026. doi.org/10.1016/j.addr.2024.115190
  6. Omuya H, Nickel C, Wilson P, Chewning B. A systematic review of randomised-controlled trials on deprescribing outcomes in older adults with polypharmacy. International Journal of Pharmacy Practice. 2023;31(4):349-368. doi:10.1093/ijpp/riad025 read 9 October 2026. doi.org/10.1093/ijpp/riad025
  7. Everhart AO, Sen S, Stern AD, et al. Association between regulatory submission characteristics and recalls of medical devices receiving 510(k) clearance. JAMA. 2023;329:144-156. read 9 October 2026. tctmd.com
  8. Shchaslyvyi AY, Antonenko SV, Tesliuk MG, Telegeev GD. Current State of Human Gene Therapy: Approved Products and Vectors. Pharmaceuticals. 2023;16(10):1416. doi:10.3390/ph16101416 read 9 October 2026. doi.org/10.3390/ph16101416
  9. Kohn DB, Chen YY, Spencer MJ. Successes and challenges in clinical gene therapy. Gene Therapy. 2023;30(10-11):738-746. doi:10.1038/s41434-023-00390-5 read 9 October 2026. doi.org/10.1038/s41434-023-00390-5
  10. Kearney B, McDermott O. The Challenges for Manufacturers of the Increased Clinical Evaluation in the European Medical Device Regulations: A Quantitative Study. Therapeutic Innovation & Regulatory Science. 2023. doi:10.1007/s43441-023-00527-z read 9 October 2026. doi.org/10.1007/s43441-023-00527-z
  11. Kadakia KT, Dhruva SS, Caraballo C, et al. Use of recalled devices in new device authorizations under the US Food and Drug Administration's 510(k) pathway and risk of subsequent recalls. JAMA. 2023;329:136-143. read 9 October 2026. tctmd.com
  12. Liu R, Luo C, Pang Z, et al. Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. Chinese Chemical Letters. 2022. doi:10.1016/j.cclet.2022.05.032 read 9 October 2026. doi.org/10.1016/j.cclet.2022.05.032
  13. Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Explanation and Elaboration: A report of the ISPOR CHEERS II Good Practices Task Force. Value in Health. 2022;25(1):10-31. read 9 October 2026. ispor.org
  14. Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. BMJ. 2022;376:e067975. read 9 October 2026. cris.iucc.ac.il
  15. Au HKE, Isalan M, Mielcarek M. Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings. Frontiers in Medicine. 2022;8. doi:10.3389/fmed.2021.809118 read 9 October 2026. doi.org/10.3389/fmed.2021.809118
  16. Zheng X, Zhang P, Fu Z, Meng S, Dai L, Yang H. Applications of nanomaterials in tissue engineering. RSC Advances. 2021;11:19041-19058. doi:10.1039/d1ra01849c read 9 October 2026. doi.org/10.1039/d1ra01849c
  17. Jiskoot W, Hawe A, Menzen T, Volkin DB, Crommelin DJA. Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: Quo Vadis? Journal of Pharmaceutical Sciences. 2021;111(4):861-867. doi:10.1016/j.xphs.2021.11.008 read 9 October 2026. doi.org/10.1016/j.xphs.2021.11.008
  18. Alhakamy NA, Curiel DT, Berkland CJ. The era of gene therapy: From preclinical development to clinical application. Drug Discovery Today. 2021;26(7):1602-1619. doi:10.1016/j.drudis.2021.03.021 read 9 October 2026. doi.org/10.1016/j.drudis.2021.03.021
  19. Hu Q, Jiang B, Liu D, Tang X, Daly T, Shameem M. Chapter 14: Practical Considerations in High Concentration Formulation Development for Monoclonal Antibody Drug Products. AAPS Advances in the Pharmaceutical Sciences Series. 2020;35:343-372. doi:10.1007/978-3-030-31415-6_14 read 9 October 2026. doi.org/10.1007/978-3-030-31415-6_14
  20. Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-853. doi:10.1001/jama.2020.1166 read 9 October 2026. doi.org/10.1001/jama.2020.1166
  21. Yu TTL, Gupta P, Ronfard V, Vertes AA, Bayon Y. Recent Progress in European Advanced Therapy Medicinal Products and Beyond. Frontiers in Bioengineering and Biotechnology. 2018;6:130. doi:10.3389/fbioe.2018.00130 read 9 October 2026. doi.org/10.3389/fbioe.2018.00130
  22. Lulla PD, Hill LC, Ramos CA, Heslop H. The use of chimeric antigen receptor T cells in patients with non-hodgkin lymphoma. Clinical Advances in Hematology and Oncology. 2018;16(5):375-386. read 9 October 2026. scholars.houstonmethodist.org
  23. Tang Z, He C, Tian H, Ding J, Hsiao BS, Chu B, Chen X. Polymeric nanostructured materials for biomedical applications. Progress in Polymer Science. 2016;60:86-128. doi:10.1016/j.progpolymsci.2016.05.005 read 9 October 2026. doi.org/10.1016/j.progpolymsci.2016.05.005
  24. Atun R, Jaffray DA, Barton MB, et al. Expanding global access to radiotherapy. The Lancet Oncology. 2015;16(10). read 9 October 2026. oncology-central.com
  25. Mitera G, Swaminath A, Rudoler D, Seereeram C, Giuliani M, Leighl N, Gutierrez E, Dobrow MJ, Coyte PC, Yung T. Cost-Effectiveness Analysis Comparing Conventional Versus Stereotactic Body Radiotherapy for Surgically Ineligible Stage I Non-Small-Cell Lung Cancer. JCO Oncology Practice. 2014;10(3):e130-e136. doi:10.1200/jop.2013.001206 read 9 October 2026. doi.org/10.1200/jop.2013.001206
  26. Committee for Advanced Therapies (CAT) and CAT Scientific Secretariat. Challenges with advanced therapy medicinal products and how to meet them. Nature Reviews Drug Discovery. 2010;9(3):195-201. doi:10.1038/nrd3052 read 9 October 2026. doi.org/10.1038/nrd3052
  27. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. The Journal of Gene Medicine. 2013;15(2):65-77. read 13 November 2026. View via DOI
  28. Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: an update. The Journal of Gene Medicine. 2018;20(5):e3015. read 13 November 2026. View via DOI
  29. Carrera-Pacheco SE, Mueller A, Puente-Pineda JA, Zúñiga-Miranda J, Guamán LP. Designing cytochrome P450 enzymes for use in cancer gene therapy. Frontiers in Bioengineering and Biotechnology. 2024;12:1405466. read 13 November 2026. View via DOI
  30. Wang M, Liu H, Huang J, Cai T, Xu ZP, Zhang L. Advancing cancer gene therapy: the emerging role of nanoparticle delivery systems. Journal of Nanobiotechnology. 2025;23(1):362. read 13 November 2026. View via DOI
  31. Bonowicz K, Jerka D, Piekarska K, et al. CRISPR-Cas9 in cardiovascular medicine: unlocking new potential for treatment. Cells. 2025;14(2):131. read 13 November 2026. View via DOI

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 9). The Role of a Contract Research Organisation in Gene Therapy Clinical Trials: Follow-Up, Vectors and Documentation. Pubrica. https://pubrica.com/academy/research/uses-of-gene-therapy-in-clinical-research-organization-list-out-few-examples/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Gene therapy programme operational readiness checklist

This checklist should be completed before the protocol is finalised. It is organised around the four structural differences rather than around study phases, because these are the points at which programmes most often fail. Each blank should be completed; an unfilled blank indicates a gap.

GENE THERAPY PROGRAMME OPERATIONAL READINESS

PROGRAMME: ____________________  INDICATION: ______________
VECTOR / DELIVERY SYSTEM: ______________________
SPONSOR: ____________________  CRO: ____________________

A. SINGLE IRREVERSIBLE ADMINISTRATION
  [ ] Eligibility criteria reviewed specifically for the fact that
      treatment cannot be withdrawn
  Pre-existing immunity / pre-treatment assays required:
      ____________________________________________
  [ ] Assay validated
  [ ] Available at every site  OR  [ ] central lab, shipping route
      documented: ____________________
  Plan for the non-reversible adverse event:
      ____________________________________________
  CONSENT states, in the patient's own terms:
  [ ] the administration cannot be reversed or discontinued
  [ ] the follow-up duration (______ years)
  [ ] shedding and household precautions, if applicable
  [ ] long-term sample storage and its purpose
  [ ] what happens if the therapy does not work

B. DURABLE EFFECT AND LONG-TERM FOLLOW-UP
  Total follow-up duration required: ______ years
  Basis for that duration: ______________________
  [ ] Long-term follow-up exists as a SEPARATE document
      Document name / number: ____________________
      Named owner: ____________________
      Named medical monitor: ____________________
      Funding line to year ______, independent of parent study
  LONG-TERM DATASET (keep it short enough to sustain):
      1. ____________________  2. ____________________
      3. ____________________  4. ____________________
      5. ____________________  6. ____________________
  Intervals: ______ / ______ / then annually to year ______
      [ ] final years by contact rather than clinic visit
  System of record: [ ] registry  [ ] separate LTFU database
                    [ ] parent trial database (NOT recommended)
  RETENTION, against the attrition mechanism:
  [ ] consent covers the full duration, taken once
  [ ] two contact routes recorded at consent
  [ ] agreement with treating centre to flag transfers of care
  [ ] something returned to the patient annually
  DURABILITY ENDPOINT, pre-specified:
      Definition: ____________________________________
      Measurement horizon: ______

C. BIOLOGICAL PRODUCT AND SITE READINESS
  [ ] Batch / lot / titre recorded as study variables
  [ ] Cold chain specification written and tested
  [ ] Import documentation prepared per country (see D)
  SITE QUALIFICATION — product-specific, not generic:
  [ ] handling and storage capability verified on site
  [ ] containment and waste handling verified
  [ ] eligibility assay capability or shipping route confirmed
  [ ] staff trained on this product, not the class
  [ ] site can sustain follow-up for ______ years

D. SMALL POPULATION AND DESIGN
  Expected eligible patients per site: ______  Total: ______
  Design: [ ] single arm  [ ] randomised  [ ] other: ________
  EXTERNAL COMPARISON, specified NOW:
      Source: ________________________________________
      Date specified: ______  (must precede any results)
      Handling of differences between groups: ______________
  Primary endpoint: ____________________
      [ ] sensitive at the achievable n
      [ ] continuous or time-to-event rather than dichotomous
  Missing data plan assumes successful patients are lost: [ ]

E. MULTICOUNTRY (complete one block per country)
  Country: ____________  Advanced-therapy requirements reviewed [ ]
  Import route documented [ ]  Lead time: ______ weeks
  Sites qualified: ______  Expected patients: ______
  [ ] This country has a viable product route, not just patients

F. EVIDENCE A PAYER WILL ASK FOR
  [ ] Durability endpoint pre-specified (see B)
  [ ] Comparator is the real-world pathway the therapy displaces
  [ ] Resource use collected prospectively:
        hospitalisations [ ]  alternative treatment use [ ]
        care pathway contacts [ ]  time off treatment [ ]
  [ ] Outcomes for non-responders collected and analysable

G. DOCUMENT OWNERSHIP
  Protocol ........................ owner ________________
  Statistical analysis plan ....... owner ________________
  Investigator's brochure ......... owner ________________
  Informed consent document ....... owner ________________
  Long-term follow-up plan ........ owner ________________
  Risk management plan ............ owner ________________
  Periodic safety reports ......... owner ________________
  Clinical study report ........... owner ________________
  [ ] No document above has a blank owner

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica writes and reviews the documents in which gene therapy programmes most often leave gaps: the long-term follow-up plan as a standalone protocol with a dataset short enough to sustain, the pre-specified external comparison and durability endpoint in the protocol and statistical analysis plan, and the consent language on irreversibility and follow-up duration. Pubrica also develops product-specific site qualification criteria that generic capability questionnaires omit, and the prospective resource-use dataset that a payer submission requires and that cannot be reconstructed afterwards.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Pubrica can review a gene therapy protocol and identify the outstanding requirements of the long-term follow-up plan and the evidence that payers will require.

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.